• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>公司动态>Life Technologies 收购美国AcroMetrix

    Life Technologies 收购美国AcroMetrix

    Life Technologies2010年1月13日 14:26 点击:3445

    美国Life Technologies   美国AcroMetrix
    Life Technologies签署最终协议,收购AcroMetrix 再添奉献的分子诊断公司的优势
    加利福尼亚州卡尔斯巴德,2010年1月12日(商业新闻) - Life Technologies(NASDAQ:LIFE),创新的生命科学解决方案提供商,今天宣布,它已经签署了数额不详的最终协议,收购AcroMetrix。
    AcroMetrix是一个分子和血清学诊断产品供应商质量控制与临床实验室,血液检测?#34892;?#21644;体外诊断(IVD)的制造商。诊断控制允许实验室取得更好的跨系统的标准化,而且更经济?#34892;?#30340;使用比“自制”控制试剂。
    随着DNA和其它分子为基础的测试增长“,有一个高?#20998;?#30340;不断增长的需求,提供独立控制,以确保准确性和完整性化验结果说,”格雷戈里吨卢西尔,董事长兼首席执行官生命科技。他说:“AcroMetrix收购基础上的。我们对进入该行业提供的分子诊断工具和技术,大量的业务”
    Life Technologies持有的分子诊断产品,包括超过300元的该公司的收入,包括诸如磁珠,荧光染料和特异性抗体,可用于诊断制造商定制设计的部件万美元的重大投?#39318;?#21512;。该公司还提供的SPOT -的乳腺癌患者的评估光(R)的HER2阳性切除术?#20934;?为自动HLA抗体筛查Dynachip(R)系统;和分子诊断仪器,如3500 DX系列遗传分析仪的诊断用清除,在某些?#20998;?#22269;家,以及7500快速霉素实时PCR仪。在7500和7500的快速快速霉素文书已收到美国食品和药物管理局紧急使用授权为甲型流感(H1N1)病毒的监察工作,并已获得全球公共卫生机构使用。
    他说:“AcroMetrix除了将加快我们的重点商业渠?#26469;?#25104;?#21152;?#30446;前的产品组合以及与客户的发展分子诊断化验,扩建,说:”马克史蒂文森,Life Technologies总裁兼首席运营官。 “我们的目标是成为技术?#29486;?#20249;伴的首选全球的组织正在构建其分子诊断能力。”
    “我们很高兴能加入我们的Life Technologies在市场分子诊断产品的全套产品,出色的线路,说:”迈克尔J埃克,总裁兼首席执行官AcroMetrix。 “我们的客户现在将受益于更大的旨在满足临床实验室需要的新的分子产品的投资。”
    该交易还取决于惯例成交条件。Life Technologies并不期望这次交易对2010财年的财务状况产生重大影响。
    关于生命科技(www.lifetechnologies.com
    生命技术公司(纳斯达?#26031;善贝?#30721;:生活)是一家全球性生物技术工具公司,致力于?#32435;?#20154;类生活条件。我们的系统,消耗品和服务,使研究人员能够加快科学探索,开车去发现和发展,使生活更加美好。Life Technologies的客户做整个生物频谱他们的工作,努力促进个性化医疗,再生科学,分子诊断,农业和环境的研究,21世纪取证。生命科技目前已经超过30亿美元的销售额在2008年,员工约9,500人,已在100多个国?#19994;?#23384;在,而且拥有迅速增长的约3600项专利和专?#34892;?#21487;的知识产权资产。Life Technologies是由对Invitrogen公司和美国应用生物系统公司的结合,同时生产体外诊断产品和研究只使用标记的产品。欲了解更多有关我们如何作出不同的信息,请访问我们的网站:www.lifetechnologies.com
    Life Technologies的安全港声明
    本新闻稿包含前瞻性对我们有?#27426;?#30340;风险和不确定性的预期结果的声明。一些在本新闻稿中包含的信息,包括但不限于,行业趋势和Life Technologies的计划,目标,预期和其商业策略,包括前瞻性陈述,受风险和不确定因素,可能导致实?#24335;?#26524;或?#24405;?#22823;不相同的表达或此类前瞻性声明所暗示的。任何声明不属于历史事实的陈述均为前瞻性陈述。在使用?#20445;?ldquo;相信”,“计划”,“打算”,“预期”,“目标”,“估计”,“期望”等,和/或将来时态或有条件的建设(“将”,“可能“,”可能“,”应该“,等等),或者类似的表达方式,这些某些前瞻性陈述。重要因素可能导致实?#24335;?#26524;与在前瞻性声明是由生活在技术方面所取得的证券交易委员会提交的文件中详细?#24471;?#30340;大不相同。Life Technologies不承担更新或修改任何前瞻性陈述以反映随后的?#24405;?#25110;情况。


    来源:Life Technologies


     

    Life Technologies新闻稿
    Life Technologies Signs Definitive Agreement to Acquire AcroMetrix

    Acquisition Adds to Company's Strengths in Molecular Diagnostic Offerings

    CARLSBAD, Calif., Jan 12, 2010 (BUSINESS WIRE) -- Life Technologies Corporation (NASDAQ: LIFE), a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire AcroMetrix, for an undisclosed amount.

    AcroMetrix is a provider of molecular and serological diagnostic quality control products to clinical laboratories, blood screening centers and in-vitro diagnostic (IVD) manufacturers. Diagnostic controls allow a laboratory to achieve better standardization across systems and are more economically efficient to use than "homebrew" control reagents.

    "With the growth of DNA and other molecular based tests, there is a growing need for high quality, independently provided controls to ensure the accuracy and integrity of laboratory test results," said Gregory T. Lucier, Chairman and Chief Executive Officer of Life Technologies. "The acquisition of AcroMetrix builds on our substantial business of providing tools and technologies into the molecular diagnostics industry."

    Life Technologies holds a significant portfolio of molecular diagnostics products that comprise more than $300 million of the company's revenue, including components such as magnetic beads, fluorescent dyes and specific antibodies, which can be custom designed for diagnostics manufacturers. The company also provides the SPOT-Light(R) HER2 CISH Kit for assessment of breast cancer patients; the Dynachip(R) System for automated HLA antibody screening; and molecular diagnostic instruments such as the 3500 Dx Series Genetic Analyzer, cleared for diagnostic use in certain European countries, and the 7500 Fast Dx Real-Time PCR instrument. The 7500 Fast and 7500 Fast Dx instruments have received Emergency Use Authorization from the Food and Drug Administration for surveillance of the Influenza A (H1N1) virus and have been used by public health agencies worldwide.

    "The addition of AcroMetrix will accelerate the expansion of our focused commercial channel for reaching molecular diagnostics customers, both with the current product portfolio and with assays in development," said Mark Stevenson, Life Technologies' President and Chief Operating Officer. "Our objective is to become the technology partner of choice to organizations worldwide that are building out their molecular diagnostic capabilities."

    "We're pleased to add our superior line of products to Life Technologies' comprehensive suite of offerings in the molecular diagnostics market," said Michael J. Eck, President and Chief Executive Officer of AcroMetrix. "Our customers will now benefit from even greater investment in new molecular products designed to meet the needs of clinical laboratories."

    The transaction is subject to customary closing conditions. Life Technologies does not expect this transaction to have a material effect on its financials in fiscal year 2010.

    About Life Technologies (www.lifetechnologies.com)

    Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: www.lifetechnologies.com.

    Life Technologies' Safe Harbor Statement

    This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

     

     

    SOURCE: Life Technologies Corporation

    Life Technologies CorporationCorporate CommunicationsFarnaz Khadem, (760) 603-7245[email protected]orInvestor RelationsEileen Pattinson, (760) 268-7408[email protected]

    (来源: Life Technologies )


    全年征稿 / 资讯?#29486;?/b>

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载?#20445;?#24517;须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    wap平特四连肖网 福彩3d六码复式论坛 广西11选五玩法 黑龙江22选5开奖结果走势图 老腾讯分分彩官方开奖 斗地主规则简明版 福彩七乐彩走势图网站 急速赛车装扮 四川时时彩qq群 上海快3怎么提现 北京11选5开奖结果查询 爱彩乐江苏快三 北单官网比分直播 广东福彩36选7今晚开奖结果查询 怎么删除头条历史记录